GENFIT addresses medical needs linked to the early management of diabetes and associated disorders. The Company conducts proprietary R&D programs in the major therapeutic areas of Cardiometabolic disorders, including prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity...
GENFIT’s programs are coordinated to focus on solutions:
- In early diagnosis, prevention, and treatment of disorders associated with prediabetes and diabetes, by approaching diabetic pathology from different perspectives,
- In the field of theranostics, by exploiting a novel cutting-edge technology to develop biomarkers that can be integrated into R&D strategies for the assessment of drug candidates.
Learn more on key programs or have a closer look at our most advanced compound in clinical development.
TARGETING DIABETES AND CARDIOVASCULAR DISORDERS
Ranging from risk factors such as lipid disorders and altered glycemia to micro- and macrovascular diseases including atherosclerosis, myocardial infarction, stroke, anddiabetic nephropathy, disorders associated with prediabetes and diabetes represent a major challenge for public health worldwide.
Through complementary approaches covering the diagnosis, prevention and treatment of these disorders, Genfit has developed a rich and diversified program pipeline of potential blockbusters in clinical and preclinical phases, as well as innovative therapeutic targets that will undeniably provide the basis for future first-in-class drugs.
Learn more about Prediabetes and Diabetes.
MOVING FORWARD IN THERANOSTICS
The concerns of the pharmaceutical industry and healthcare authorities are such that it is clearly of great interest to possess tools that enable the rapid and precise assessment of patient responses to new therapeutic treatments.
GENFIT has made major advances in the development of a cutting-edge non-invasive, non-imaging biomarker technology, that should enable a fast, focused and predictive analysis of the effectiveness of new treatments dedicated to certain metabolic diseases.
OUR INNOVATION NETWORK
GENFIT has initiated and leads several research consortia in collaboration with academic institutions and other biotech companies. Partnerships of this type are a rich source of scientific and technological innovation, and are increasingly sought by the pharmaceutical industry. The management of such consortia is also a valuable source of revenue, in the form of national or European grants and loans designed to favor the development of biotechnology companies.
The IT-Diab consortium led by GENFIT aims to identify new targets implicated in the progression from prediabetes to Type 2 diabetes, and early biomarkers of this progression, with a focus on pancreatic -cell dysfunction. The consortium is built around a major longitudinal clinical research plan that progressed significantly in 2010 with the launch of two important clinical trials:
- In June 2010, recruitment began for the DECODIAB study, that will prospectively monitor the evolution from prediabetes to Type 2 diabetes in 500 hyperglycemic patients over a period of 5 years. It will enable the identification and validation of new biomarkers of -cell dysfunction in this at-risk population.
- In July 2010, recruitment began for the REVERSY study, that will analyze the association between glycemic status, obesity, and tissue gene expression. The study involves the longitudinal follow-up of 900 bariatric surgery patients suffering from morbid obesity, and has enabled GENFIT to access precious phenotypic data and biological samples for its therapeutic target and biomarker identification programs in prediabetes and early Type 2 diabetes.
